BTS
ESPR

BB&T Securities’s Esperion Therapeutics ESPR Stock Holding History

BB&T Securities’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,000
Closed -$289K – 1565
2018
Q1 		$289K Hold
4,000
– – ﹤0.01% 1251
2017
Q4 		$263K Buy
+4,000
New +$215K ﹤0.01% 1234

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BB&T Securities's ESPR Position: Q2 2018 in Review

BB&T Securities sold out of Esperion Therapeutics (ESPR) in Q2 2018, closing a stake of 4,000 shares — an estimated $289K sold.

BB&T Securities first reported a position in ESPR in Q4 2017 and held it in 2 quarters. The position peaked at $289K in Q1 2018. 156 funds tracked by Wall St. Rank hold ESPR as of Q2 2018.

  • BB&T Securities reported no remaining Esperion Therapeutics position as of Q2 2018 after selling out during the quarter.
  • BB&T Securities sold 4,000 Esperion Therapeutics shares in Q2 2018, an estimated $289K.
  • BB&T Securities first reported a position in Esperion Therapeutics in Q4 2017 and held it in 2 quarters.
  • BB&T Securities's Esperion Therapeutics position peaked at $289K in Q1 2018.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2018.

Based on BB&T Securities's 13F filing for Q2 2018, filed 13 Aug 2018.